Company intelligence / Profile preview

PRR

Adelaide, South Australia, Australia

Ownership: Private
Development stage: Other

Overview

PRR Therapeutics is an Australian biotechnology company focused on developing first-in-class therapies that target the (Pro)renin Receptor (PRR), also known as ATP6AP2. The company leverages its expertise in the renin-angiotensin system to address diseases driven by PRR-mediated signaling, including various forms of cancer and fibrotic disorders. Their primary focus is on pancreatic cancer, where PRR is overexpressed and promotes tumor growth, and chronic kidney disease, where it drives fibrosis. PRR Therapeutics is advancing a pipeline of peptide-based and small molecule inhibitors designed to block PRR activation and its downstream pathological effects.

Therapeutic areas: OncologyNephrologyOphthalmologyOther
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on PRR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRR.

Explore the full profile